International Journal of Molecular Sciences | |
Synthesis and Biological Activities of a 3'-Azido Analogue of Doxorubicin Against Drug-Resistant Cancer Cells | |
Shuwen Yu3  Guisheng Zhang2  Wenpeng Zhang4  Huanhua Luo1  Liyun Qiu1  Qingfeng Liu2  Duxin Sun5  Peng-George Wang4  | |
[1] Jinan Central Hospital Affiliated to Shandong University, Jinan 250011, China; E-Mails:;College of Chemistry and Environmental Sciences, Henan Normal University, Xinxiang 453002, China; E-Mails:;School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China; E-Mail:;Department of Chemistry and Biochemistry, The Ohio State University, Ohio 43210, USA; E-Mail:;College of Pharmacy, The University of Michigan, Michigan 48109, USA; E-Mail: | |
关键词: anthracycline; Azido; multidrug resistance; ADOX; P-gp; | |
DOI : 10.3390/ijms13033671 | |
来源: mdpi | |
【 摘 要 】
Doxorubicin (DOX), an anthracycline antibiotic, is one of the most active anticancer chemotherapeutic agents. The clinical use of DOX, however, is limited by the dose-dependant P-glycoprotein (P-gp)-mediated resistance. Herein, a 3′-azido analogue of DOX (ADOX) was prepared from daunorubicin (DNR). ADOX exhibited potent antitumor activities in drug-sensitive (MCF-7 and K562) and drug-resistant cell lines (MCF-7/DNR, K562/DOX), respectively. The drug resistance index (DRI) values of ADOX were much lower than that of DOX. The cytotoxicity experiments of ADOX or DOX against K562/DOX, with or without P-gp inhibitor, indicated that ADOX circumvents resistance by abolishing the P-gp recognition. This conclusion was further supported by drug influx/efflux flow cytometry experiments, as well as by molecular docking of ADOX to P-gp.
【 授权许可】
CC BY
© 2012 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland.
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202003190045054ZK.pdf | 467KB | download |